ENGINEERED BIOSYNTHESIS OF NOVEL KETOLIDE ANTIBIOTICS
新型酮内酯抗生素的工程生物合成
基本信息
- 批准号:6135032
- 负责人:
- 金额:$ 16.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-08-01 至 2002-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Ketolide antibiotics have recently attracted significant interest because they have activity against a number ofmacrolide-resistant microorganisms, in particular staphylococci and enterococci. The overall objective of this research program is to use combinatorial biosynthesis and biochemical pathway engineering to produce novel functionalized ketolide antibiotics. A combination of two technologies belonging to Virginia Commonwealth University (VCU), and Midwest Molecular (a small business located in Minneapolis, Minnesota) will be used to achieve this goal. The VCU technology comprises a gene cassette capable of in vivo generation of a range of novel hydroxylated and desaturated cyclohexanecarboxylic acid starter units for polyketide biosynthesis. The Midwest Molecular technology is a set of versatile pikromycin polyketide biosynthetic enzymes for production of 14-membered ketolide antibiotics that can be engineered to accept these novel starter units. PROPOSED COMMERCIAL APPLICATIONS: Ketolides hold promise as a solution to the increase in erythromycin- resistant bacterial pathogens, including Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus and some enterococci. Numerous large pharmaceutical companies have semisynthetic ketolides which are now in phase II clinical trials. The proposed research will use a genetic-based precursor-directed biosynthetic technology in combination with polyketide synthase genetic engineering, to generate in an economically viable manner a range of novel ketolides not available from other technologies.
酮类抗生素最近引起了极大的兴趣,因为它们对许多大环内酯类耐药微生物,特别是葡萄球菌和肠球菌具有活性。本研究计划的总体目标是利用组合生物合成和生化途径工程来生产新型功能化酮内酯类抗生素。弗吉尼亚联邦大学(VCU)和中西部分子公司(位于明尼苏达州明尼阿波利斯市的一家小型企业)的两项技术的组合将用于实现这一目标。 VCU技术包括能够在体内产生用于聚酮化合物生物合成的一系列新型羟基化和去饱和环己烷羧酸起始单元的基因盒。中西部分子技术是一套多功能的匹克罗霉素聚酮生物合成酶,用于生产14元酮内酯类抗生素,可通过工程改造接受这些新型起始单元。拟议的商业应用:酮内酯有望作为红霉素耐药性细菌病原体增加的解决方案,包括化脓性链球菌、肺炎链球菌、金黄色葡萄球菌和一些肠球菌。许多大型制药公司都有半合成酮内酯,目前正处于II期临床试验阶段。拟议的研究将使用一种基于遗传的生物合成技术与聚酮合酶基因工程相结合,以经济可行的方式产生一系列其他技术无法获得的新型酮内酯。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEVIN A REYNOLDS其他文献
KEVIN A REYNOLDS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEVIN A REYNOLDS', 18)}}的其他基金
Hygromycin A: Activity, Biosynthesis, Export, Resistance and Regulation
潮霉素 A:活性、生物合成、输出、耐药性和监管
- 批准号:
8537947 - 财政年份:2011
- 资助金额:
$ 16.63万 - 项目类别:
Hygromycin A: Activity, Biosynthesis, Export, Resistance and Regulation
潮霉素 A:活性、生物合成、输出、耐药性和监管
- 批准号:
8727602 - 财政年份:2011
- 资助金额:
$ 16.63万 - 项目类别:
Hygromycin A: Activity, Biosynthesis, Export, Resistance and Regulation
潮霉素 A:活性、生物合成、输出、耐药性和监管
- 批准号:
8023746 - 财政年份:2011
- 资助金额:
$ 16.63万 - 项目类别:
Hygromycin A: Activity, Biosynthesis, Export, Resistance and Regulation
潮霉素 A:活性、生物合成、输出、耐药性和监管
- 批准号:
8335367 - 财政年份:2011
- 资助金额:
$ 16.63万 - 项目类别:
Deciphering the steps of prodiginine biosynthesis
破译原地吉宁生物合成步骤
- 批准号:
7414458 - 财政年份:2007
- 资助金额:
$ 16.63万 - 项目类别:
Deciphering the steps of prodiginine biosynthesis
破译原地吉宁生物合成步骤
- 批准号:
7634480 - 财政年份:2007
- 资助金额:
$ 16.63万 - 项目类别:
Deciphering the steps of prodiginine biosynthesis
破译原地吉宁生物合成步骤
- 批准号:
7914938 - 财政年份:2007
- 资助金额:
$ 16.63万 - 项目类别:
Deciphering the steps of prodiginine biosynthesis
破译原地吉宁生物合成步骤
- 批准号:
7264876 - 财政年份:2007
- 资助金额:
$ 16.63万 - 项目类别:
Deciphering the steps of prodiginine biosynthesis
破译原地吉宁生物合成步骤
- 批准号:
7849695 - 财政年份:2007
- 资助金额:
$ 16.63万 - 项目类别:
3-Ketoacyl ACP Synthase III: A Novel Antibiotic Target
3-酮脂酰 ACP 合酶 III:新型抗生素靶点
- 批准号:
7095655 - 财政年份:2005
- 资助金额:
$ 16.63万 - 项目类别:
相似海外基金
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
- 批准号:
2884862 - 财政年份:2023
- 资助金额:
$ 16.63万 - 项目类别:
Studentship
Disrupting Dogma: Investigating LPS Biosynthesis Inhibition as an Alternative Mechanism of Action of Aminoglycoside Antibiotics
颠覆教条:研究 LPS 生物合成抑制作为氨基糖苷类抗生素的替代作用机制
- 批准号:
10653587 - 财政年份:2023
- 资助金额:
$ 16.63万 - 项目类别:
Simulation-led engineering of Diels-Alderase activity and selectivity for sustainable biosynthesis of new antibiotics
模拟主导的 Diels-Alderase 活性和选择性工程,用于新型抗生素的可持续生物合成
- 批准号:
2881671 - 财政年份:2023
- 资助金额:
$ 16.63万 - 项目类别:
Studentship
Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes
通过真菌人工染色体的发育,快速剖析嗜极真菌共培养中产生的抗 MRSA 抗生素的生物合成
- 批准号:
10546657 - 财政年份:2022
- 资助金额:
$ 16.63万 - 项目类别:
Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes
通过真菌人工染色体的发育,快速剖析嗜极真菌共培养中产生的抗 MRSA 抗生素的生物合成
- 批准号:
10657805 - 财政年份:2022
- 资助金额:
$ 16.63万 - 项目类别:
Engineering Monobactam Biosynthesis towards the Generation of Novel β-Lactam Antibiotics
工程单菌素生物合成以产生新型β-内酰胺抗生素
- 批准号:
492438365 - 财政年份:2021
- 资助金额:
$ 16.63万 - 项目类别:
WBP Fellowship
Regulation, biosynthesis and mode of action of formicamycins, promising new antibiotics with a high barrier to resistanc
福米霉素的调控、生物合成和作用方式,有望成为具有高耐药屏障的新型抗生素
- 批准号:
BB/S00811X/2 - 财政年份:2020
- 资助金额:
$ 16.63万 - 项目类别:
Research Grant
Regulation of formicamycin biosynthesis: new potent antibiotics against MRSA
福米霉素生物合成的调控:抗 MRSA 的新型强效抗生素
- 批准号:
2239940 - 财政年份:2019
- 资助金额:
$ 16.63万 - 项目类别:
Studentship
Enzyme cooperativity in the biosynthesis of antibiotics and their cellular target structures (B06)
抗生素生物合成及其细胞靶结构中的酶协同作用(B06)
- 批准号:
425876999 - 财政年份:2019
- 资助金额:
$ 16.63万 - 项目类别:
CRC/Transregios
Regulation, biosynthesis and mode of action of formicamycins, promising new antibiotics with a high barrier to resistanc
福米霉素的调控、生物合成和作用方式,有望成为具有高耐药屏障的新型抗生素
- 批准号:
BB/S00811X/1 - 财政年份:2019
- 资助金额:
$ 16.63万 - 项目类别:
Research Grant